Association of Pre-Existing Antithrombotic Therapy With Clinical Outcomes in Patients with Acute Dengue Infection.

Authors

Po-Tseng Lee, Ling-Wei Hsu, Mu-Shiang Huang, Po-Lin Chen, Tharmaraj Vairaperumal, Ling-Shan Syue, Po-Kai Yang, Wen-Chien Ko, Ping-Yen Liu

Published in

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109087. Aug 29, 2026. Epub Aug 29, 2026.

Abstract

Dengue infection frequently causes thrombocytopenia and bleeding complications. Patients with cardiovascular disease who receive antiplatelet or anticoagulant therapy represent a clinically challenging population during acute dengue infection. Data regarding clinical outcomes and platelet recovery in these patients remain limited.
This observational study included a single-center retrospective cardiovascular dengue cohort and an exploratory platelet-monitoring cohort. In the retrospective cohort, patients were classified according to pre-existing antithrombotic therapy (ATT) at dengue diagnosis: no antithrombotic therapy (No ATT), single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT), or oral anticoagulant therapy (OAC). Major bleeding was assessed within 7 and 30 days after dengue diagnosis. In the exploratory platelet-monitoring cohort, serial platelet count and platelet function were assessed during dengue illness.
The retrospective cohort included 1,693 patients (No ATT, n = 1,493; SAPT, n = 163; DAPT, n = 22; OAC, n = 15). ATT users were older and had a greater burden of cardiovascular comorbidities and more frequent severe dengue manifestations. The observed 7-day major bleeding rates in the No ATT, SAPT, DAPT, and OAC groups were 0.34%, 0.61%, 4.55%, and 6.67%, respectively (P = 0.011), with corresponding 30-day rates of 1.15%, 1.84%, 9.09%, and 13.33% (P = 0.002). In the exploratory platelet-monitoring cohort (6 non-antiplatelet users and 2 aspirin users), aspirin users had a longer platelet count nadir-to-recovery time than non-antiplatelet users [median (IQR), 7.5 (6.0-9.0) vs 4.0 (3.75-4.25) days; P = 0.04] and a longer interval from the lowest platelet function value to recovery [median (IQR), 9.5 (8.0-11.0) vs 4.0 (3.75-4.25) days; P = 0.04].
Pre-existing ATT users had a greater comorbidity burden and more severe dengue manifestations. SAPT users showed similar observed short-term major bleeding rates to patients without ATT. Exploratory monitoring suggested delayed platelet count and function recovery among aspirin users.

PMID:
42668060
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.